Search
Alumis Inc
ALMSAdd to Watchlist
23.410USD
+0.360+1.56%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
2.98BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Alumis Inc is 9.09, ranking 13 out of 389 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 25.00 and a low of 14.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
40.100
Target Price
+73.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Alumis Inc
ALMS
11
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Alumis Inc's expected revenue for the next quarter?
Alumis Inc's expected revenue is 4.02M.
What is Alumis Inc's price target?
Analysts forecast that Alumis Inc's price target is USD 18.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 14.00.
How have Alumis IncALMS's recent earnings per share performed?
The market expectation was USD -0.74, while Alumis IncALMS's earnings per share (EPS) for the previous quarter was USD -0.89. EPS for the next quarter is expected at USD -0.72.
What is the analyst rating for Alumis Inc?
Based on the ratings of Alumis Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
